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Aims Activation of vascular endothelial cells (ECs) contributes importantly to inﬂammation and atherogenesis. We previ-
ously reported that apolipoprotein CIII (apoCIII), found abundantly on circulating triglyceride-rich lipoproteins,
enhances adhesion of human monocytes to ECs in vitro. Statins may exert lipid-independent anti-inﬂammatory
effects. The present study examined whether statins suppress apoCIII-induced EC activation in vitro and in vivo.
Methods and
results
Physiologically relevant concentrations of puriﬁed human apoCIII enhanced attachment of the monocyte-like cell line
THP-1 to human saphenous vein ECs (HSVECs) or human coronary artery ECs (HCAECs) under both static and
laminar shear stress conditions. This process mainly depends on vascular cell adhesion molecule-1 (VCAM-1), as
a blocking VCAM-1 antibody abolished apoCIII-induced monocyte adhesion. ApoCIII signiﬁcantly increased
VCAM-1 expression in HSVECs and HCAECs. Pre-treatment with statins suppressed apoCIII-induced VCAM-1 ex-
pression and monocyte adhesion, with two lipophilic statins (pitavastatin and atorvastatin) exhibiting inhibitory effects
at lower concentration than those of hydrophilic pravastatin. Nuclear factor kB (NF-kB) mediated apoCIII-induced
VCAM-1 expression, as demonstrated via loss-of-function experiments, and pitavastatin treatment suppressed NF-kB
activation. Furthermore, in the aorta of hypercholesterolaemic Ldlr
2/2 mice, pitavastatin administration in vivo sup-
pressed VCAM-1 mRNA and protein, induced by apoCIII bolus injection. Similarly, in a subcutaneous dorsal air
pouch mouse model of leucocyte recruitment, apoCIII injection induced F4/80+ monocyte and macrophage accu-
mulation, whereas pitavastatin administration reduced this effect.
Conclusions These ﬁndings further establish the direct role of apoCIII in atherogenesis and suggest that anti-inﬂammatory effects
of statins could improve vascular disease in the population with elevated plasma apoCIII.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Apolipoprotein CIII † Vascular endothelial cells † Monocytes † HMG-CoA reductase inhibitors †
Atherosclerosis
Introduction
Atherosclerosis is a chronic inﬂammatory disease.
1,2 Expression of
adhesion molecules, including vascular cell adhesion molecule-1
(VCAM-1), by activated endothelial cells (ECs) plays an important
role in the initiation of arterial inﬂammation by mediating ﬁrm ad-
hesion, diapedesis, and retention of mononuclear leucocytes to the
intima of the blood vessel wall.
3,4 The recruitment of inﬂammatory
cells into the vascular intima also contributes to the progression
and instability of atherosclerotic plaques.
2,5
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doi:10.1093/eurheartj/ehs271Much effort has explored the inciting factors for the activation of
vascular EC and the pathogenesis of atherosclerosis. Increasing
evidence demonstrates that apolipoprotein CIII (apoCIII), a surface
protein component that abundantly presents on circulating
triglyceride-rich apoB lipoproteins and HDL, is a strong contributor
to atherosclerosis. Plasma levels of apoCIII and the lipoproteins that
carry apoCIII independently predict increased risk for coronary
heart disease in prospective human cohorts after adjusting for
blood lipids.
6–8 Overexpression of apoCIII causes hyperlipidaemia
and promotes atherosclerotic lesion development in mouse
models,
9 while apoCIII deﬁciency protects against dyslipidaemia
and atherogenesis.
10 ApoCIII also promotes pancreatic b-cell
death,
11,12 while antisense treatment against apoCIII delays the
onset of type 1 diabetes in rats.
13 We recently reported that
apoCIII promotes hyperlipidaemia in humans by inhibiting clearance
of plasmatriglyceride-rich lipoproteins and channeling them to con-
version to small, dense LDL.
14 In addition to its adverse effects on
blood lipids, we and others also have reported that apoCIII alone,
or as a component of VLDL or LDL, induces monocyte activation
and adhesion to ECs.
15,16 These ﬁndings suggest that apoCIII plays
a causal role in atherosclerotic lesion development independent of
its deleterious effects on lipid metabolism.
Potent cholesterol-lowering drugs 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins) reduce
the progression of atherosclerotic lesions and the onset of acute
thrombotic complications of coronary atherosclerosis.
17 In add-
ition to lipid lowering, statins may exert pleiotropic effects inde-
pendent of their regulation of cholesterol metabolism.
18 In the
present study, we tested the hypothesis in vitro and in vivo that
statins suppress apoCIII-induced EC activation and monocyte ad-
hesion, key events in early atherogenesis.
Methods
A detailed Methods section is available as Supplementary material
online.
Results
Apolipoprotein CIII induces vascular cell
adhesion molecule-1 expression in human
arterial and venous endothelial cells
in vitro
For reference, plasma apoCIII concentration ranges from 50 to
100 mg/mL in normolipidaemic humans, while hyperlipidaemic
patients have higher levels.
7 When we applied clinically relevant
concentrations of puriﬁed human apoCIII protein, we found that
apoCIII treatment signiﬁcantly affected VCAM-1 expression in cul-
tured human saphenous vein ECs (HSVECs) (ANOVA P ¼ 0.012),
and furthermore apoCIII induced VCAM-1 expression in a
dose-dependent manner (Figure 1A, P , 0.05 for linear regression
analysis using apoCIII concentration as independent variable).
The expression of ICAM-1, another major adhesion molecule,
was not signiﬁcantly affected. Similarly, physiological concentra-
tions of apoB lipoproteins (VLDL and LDL) containing apoCIII, iso-
lated from fresh human plasma, signiﬁcantly increased the
expression of VCAM-1, but not ICAM-1, compared with the
same concentrations of apoB lipoproteins without apoCIII, indicat-
ing that VCAM-1-inducing effect was due to apoCIII (Figure 1B).
ApoCIII concentration in apoCIII-containing apoB lipoproteins
was  15–30 mg/mL. In addition to HSVECs, puriﬁed apoCIII
also induced expression of VCAM-1 in a dose-dependent
manner in cultured human coronary artery ECs (HCAECs)
(Figure 1C, P , 0.05 for linear regression analysis using apoCIII con-
centration as independent variable). VCAM-1 activation in
HCAECs requires higher concentrations of apoCIII compared
with HSVECs but still in the range found in mild–to-moderate
hyperlipidaemia.
Figure 1 ApoCIII induces expression of VCAM-1 in cultured
human venous and arterial vascular ECs. Conﬂuent HSVECs
were incubated with puriﬁed human apoCIII at indicated concen-
trations (A) or apoB lipoproteins with apoCIII (apoCIII+) or
without apoCIII (apoCIII-) isolated from fresh human plasma by
immunoafﬁnity chromatography (apoB concentration 100 mg/
mL) (B). Concentration of apoCIII in apoB lipoproteins is
between 15 and 30 mg/mL. HSVECs were lysed 3 h after treat-
ment, and we performed real-time qPCR to measure VCAM-1
and ICAM-1 expression. In other experiments, conﬂuent
HCAECs were incubated with puriﬁed human apoCIII (C). Data
represent mean+SEM from multiple experiments with
HSVECs or HCAECs from different donors. *P , 0.05 between
treatment and control [Dunnett’s test for (A and C); unpaired
t-test for (B)] and
†P , 0.05 between apoB lipoproteins with
and without apoCIII (unpaired t-test).
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CIII-induced vascular cell adhesion
molecule-1 expression in human arterial
and venous endothelial cells
We pre-treated HSVECs and HCAECs with statins before
administration of puriﬁed human apoCIII and examined the
effects of statins on apoCIII-induced EC activation. We applied
two lipophilic statins (pitavastatin and atorvastatin) and one
hydrophilic statin (pravastatin). Our results showed that statins
overall affected apoCIII-induced VCAM-1 expression (Figure 2A–
C, ANOVA P , 0.05). Pitavastatin and atorvastatin attenuated
apoCIII-induced VCAM-1 expression in HSVECs (Figure 2A, P ,
0.05 Dunnett’s test), but pravastatin did not exert this effect
at the concentrations used (50–500 nM). To achieve a similar
magnitude of reduction in apoCIII-induced VCAM-1 expression
by statins in HSVECs, the minimum concentrations required
were different among the three statins (pitavastatin ,
atorvastatin , pravastatin, Figure 2B). Notably, 50 nM of pitavasta-
tin is clinically achievable. Similar to what was observed in
HSVECs, statin pre-treatment also attenuated apoCIII-induced
VCAM-1 expression in HCAECs (Figure 2C). These concentrations
of statins did not affect cell viability of HSVECs substantially (MTS
assay, Supplementary material online, Figure S1, ANOVA P ¼
0.56). Unlike VCAM-1 induction, apoCIII or statins did not
affect eNOS mRNA expression or NO production, as measured
by nitrite concentration in the cell culture supernatant, in HSVECs
(Figure 2D and E, ANOVA P ¼ NS).
Figure 2 Statin treatment attenuates apoCIII-induced VCAM-1 expression in cultured human vascular ECs. Conﬂuent HSVECs or HCAECs
were incubated with pitavastatin, atorvastatin, and pravastatin at indicated concentrations for 12 h before treatment with puriﬁed human apoCIII
for additional 4 h. Expression of VCAM-1 (A–C) or eNOS (D) was determined by qPCR. (A and D) HSVECs were treated with 50, 100, and
500 nM of statins plus 50 mg/mL apoCIII. (B) HSVECs from the same donors were treated with statins at speciﬁed concentrations. (C) HCAECs
were treated with statins plus 200 mg/mL apoCIII (P ¼ NS for ANOVA). (E) In some other experiments, nitrite concentration in the super-
natant of HSVECs cultured on 96-well plates was measured by a colorimetric assay kit 8 h after apoCIII treatment (P ¼ NS for ANOVA).
Data represent mean+SEM from multiple experiments with HSVECs or HCAECs from different donors. *P , 0.05 between apoCIII treat-
ment (unpaired t-test) and control and
†P , 0.05 between statin treatment and apoCIII alone (Dunnett’s test).
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CIII-induced monocyte adhesion to
endothelial cells under static conditions
To examine whether VCAM-1 induction increases monocyte adhe-
sion, weperformedmonocyte–ECadhesionassayunderstaticcon-
ditions. We cultured HSVECs in 96-well plates with statins prior to
addition of 50 mg/mL of puriﬁed human apoCIII, and measured the
adherence of ﬂuorescence-labelled THP-1 cells. ApoCIII treatment
signiﬁcantly altered the adhesion of THP-1 to HSVECs after apoCIII
treatment (Figure 3A–C, ANOVA P , 0.05). VCAM-1 appeared to
mediate this increased adhesion because the addition of VCAM-1-
neutralizing antibody abolished apoCIII-induced monocyte adhe-
sion, whereas control antibody had no effect (Figure 3A). Treatment
of cultured HSVECs with lipophilic pitavastatin and atorvastatin sig-
niﬁcantly reduced monocyte adhesion at lowerconcentrationsthan
those of pravastatin (Figure 3B). In addition to THP-1, we further
examined the effects of statins and apoCIII on the adhesion of
human primary monocytes to HCAECs. ApoCIII induced adhesion
of peripheral blood-derived CD14+ cells to HCAECs, which was
signiﬁcantly reduced by statin pre-treatment (Figure 3C).
Statin treatment reduces apolipoprotein
CIII-induced monocyte adhesion to
endothelial cells under laminar ﬂow
We then performed monocyte adhesion assays under laminar shear
ﬂowconditions.Wepre-treatedHSVECswithstatinsfollowedbyin-
cubation with apoCIII, and recorded adhesion of THP-1 cells.
ANOVA analysis showed that statin pre-treatment signiﬁcantly
affected apoCIII-induced adhesion of THP-1 cells to HSVECs
(Figure 4, ANOVA P , 0.05 for all panels). Analysis of video record-
ings showed that pre-treatment with lipophilic statins signiﬁcantly
reduced apoCIII-induced monocyte adhesion to the HSVEC mono-
layer(representativestillimages,Figure4A). Pitavastatinand atorvas-
tatin produced statistically signiﬁcant reductions in apoCIII-induced
THP-1 adhesion under laminar ﬂow (Figure 4B and C). At shear
stress level of 0.75 dyne/cm
2, statin treatment reduced
apoCIII-induced THP-1 adhesion (Figure 4B). When the shear
stress decreased to 0.50 dyne/cm
2, this pattern persisted and we
observed more monocyte adhesion overall (Figure 4C). At higher
concentration, pravastatin also reduced apoCIII-induced monocyte
adhesion (Figure 4D–F). The addition of the VCAM-1 monoclonal
blocking monoclonal antibody (clone E1/6) almostcompletely abol-
ished apoCIII-induced monocyte adhesion to HSVECs but not the
control monoclonal antibody that recognizes VE-cadherin (clone
HEC 1.2), indicating that THP-1 adhesion depends on VCAM-1
(Figure4D–F).SimilartowhatwasobservedforHSVECs,statinpre-
treatment also signiﬁcantly reduced apoCIII-induced THP-1 adhe-
sion to HCAECs under laminar ﬂow conditions (Figure 4G–I).
Statin administration reduces
apolipoprotein CIII-induced vascular
endothelial cell activation in vivo
To investigate the inhibitory effects of statins on apoCIII-triggered
vascular EC activation in vivo, we administered puriﬁed human
apoCIII via tail vein injection (200 mg apoCIII) to hypercholestero-
laemic Ldlr
2/2 mice on high-fat diet for 12 weeks that were treated
with pitavastatin. We administered pitavastatin by oral gavage for 5
days at the physiological dosage of 60 mg/day/kg body weight.
Figure 3 Statin treatment attenuates apoCIII-induced mono-
cyte adhesion to cultured human primary ECs under static con-
dition. Conﬂuent HSVECs or HCAECs were cultured on
96-well plates with pitavastatin, atorvastatin, and pravastatin at
speciﬁed concentrations for 12 h before the addition of puriﬁed
human apoCIII (ﬁnal concentration 50 mg/mL). After another
16 h, THP-1 cells, a human monocytic cell line (A and B), or
human primary CD14+ monocytes (C) (cell density: 1 × 10
5/
mL) labelled with BCECF-A were added into each well, and
allowed to adhere for 10 min. Non-adherent cells were
removed by washing, the ﬂuorescent intensity of adhered and
total cells applied to the well was measured by a ﬂuorescence
plate reader, and the ratio of adherent to total cells was calcu-
lated. (A) Quantiﬁed results of the percentage of THP-1 cells
attached to HSVEC-covered 96-well plates. HSVECs from the
same donors were treated with statins at speciﬁed concentra-
tions. (B) THP-1 cells were applied to HSVECs treated with 50,
100, and 500 nM of statins. (C) Human CD14+ monocytes
were applied to HCAECs treated with statins. Data represent
mean+SEM from multiple experiments with HSVECs from dif-
ferent donors. *P , 0.05 between apoCIII treatment and
control (unpaired t-test) and
†P , 0.05 between statin treatment
and apoCIII alone (Dunnett’s test).
C. Zheng et al. 618Figure 4 Statin treatment attenuates apoCIII-induced THP-1 cell adhesion to cultured human primary ECs under unidirectional laminar ﬂow.
Conﬂuent HSVECs or HCAECs cultured on ﬁbronectin-coated 25 mm glass coverslips were incubated with pitavastatin, atorvastatin, and pravas-
tatin at speciﬁed concentrations for 12 h before the addition of puriﬁed human apoCIII (50 mg/mL). After 16 h, these coverslips were inserted into
aninvitroﬂowchamberand5 × 10
5/mLTHP-1cellsinDPBScontaining0.1%HSAweredrawnacrosstheECmonolayerﬁrstat0.75 dyne/mm
2and
then at 0.50 dyne/mm
2. THP-1 adhesion was recorded by digital video microscopy and the adhesion of THP-1 cells was assessed as previously
described.
15 (A, D, and G) Representative still images of THP-1 cells attachment to HSVECs or HCAECs at indicated conditions. (B, C, E, and F)
Quantiﬁed results of the number of THP-1 cells attached to HSVECs after treatment with apoCIII and statins at indicated concentrations.
(H andI) Quantiﬁedresults ofthenumberofTHP-1 cellsattached toHCAECs after treatmentwith apoCIII andstatins at indicated concentrations.
Data represent mean+SEM from multiple experiments from different donors of HSVECs or HCAECs. *P , 0.05 between apoCIII treatment and
control (unpaired t-test);
†P , 0.05 and
‡P , 0.01 between statin treatment and apoCIII alone (Dunnett’s test).
Statins suppress apoCIII-induced vascular EC activation and monocyte adhesion 619Bolus injection of this physiologically relevant amount of apoCIII
(200 mg apoCIII) induced accumulation of VCAM-1 at the aortic
arch (Figure 5A). Our image analysis colocalized immunoreactive
VCAM-1 with CD31, a well-characterized EC marker. Pitavastatin
administration reduced apoCIII-induced VCAM-1 expression to
the levels similar to control mice. Quantitative analysis showed
that apoCIII injection increased the VCAM-1 immunopositive
area in aortic endothelium by 2.6-fold and pitavastatin administra-
tion signiﬁcantly reduced this increase (Figure 5B). Similarly, pitavas-
tatin abolished elevation of VCAM-1 mRNA levels in the lysates of
aorta following apoCIII injection (Figure 5C).
Statin administration reduces
apolipoprotein CIII-induced monocyte
transmigration in vivo
Using a mouse air pouch model of leucocyte recruitment, we fur-
thermore explored another line of in vivo evidence for the effects
of pitavstatin on apoCIII-mediated inﬂammation and monocyte/
macrophage inﬁltration. After pre-treating wild-type C57BL/6
mice with pitavastatin via gavage (60 mg/day/kg body weight), we
injected apoCIII (200 mg) to the air pouch to induce leucocyte in-
ﬁltration. We analysed the cell contents of the air pouch cavity
24 h after apoCIII injection through ﬂuorescence-activated cell
sorting (FACS), and found that apoCIII injection signiﬁcantly
induced the percentage as well as the total cell number of mono-
cytes/macrophages (F4/80+)( Figure 5D–F). Oral administration of
pitavastatin almost completely abrogated these apoCIII’s effects on
inﬁltration of cells, including monocytes/macrophages into the air
pouch.
Nuclear factor kB mediates
apoCIII-induced endothelial cell
activation
Transcription factor nuclear factor kB (NF-kB) is a key regulator of
vascular inﬂammatory reactions and drives expression of various
atherogenic molecules, including VCAM-1. ApoCIII induced
NF-kB activation in HSVECs as evidenced by the nuclear location
of its p65 subunit (Figure 6A). In addition, an inhibitor peptide to
NF-kB, SN50, signiﬁcantly reduced apoCIII-induced VCAM-1 ex-
pression in these cells (Figure 6B), indicating that apoCIII-induced
EC activation is dependent on NF-kB. In addition, pitavastatin
treatment at a clinically achievable concentration (50 nM) signiﬁ-
cantly attenuated apoCIII-induced NF-kB activation (Figure 6A).
Therefore, inhibition of the NF-kB pathway may be the major
mechanism by which statins reduce apoCIII-triggered EC activa-
tion. On the other hand, in contrast to apoCIII-induced activation
of mitogen-activated protein (MAP) kinase components p38,
ERK1/2, and JNK observed in pancreatic b-cells,
11,12 pre-treatment
of HSVECs with inhibitors of p38, ERK1/2, and JNK did not affect
apoCIII-induced VCAM-1 activation (Figure 6C, ANOVA P ¼ NS
for apoCIII-treated cells with or without inhibitors).
Discussion
Recent research by our group and others has established that
apoCIII, a well-characterized regulator of lipid metabolism, can
also act independently of its effects on lipoproteins to promote in-
ﬂammation in vascular cells
15,16 and pathological changes in other
cell types.
11–13 Owing to its lipid-independent and lipid-dependent
effects in atherogenesis, apoCIII appears to be an attractive target
for pharmacological intervention in patients with hyperlipidaemia.
In this study, we demonstrated that statin treatment reduced
apoCIII-induced pro-inﬂammatory and pro-atherogenic reactions
in venous and arterial vascular ECs in vivo and in vitro. Statins direct-
ly inhibited apoCIII-induced EC activation as assessed by expres-
sion of adhesion molecules, monocyte adhesion and activation of
the pro-inﬂammatory NF-kB pathway, independent from their
cholesterol-lowering effects. To our knowledge, this study is the
ﬁrst in vivo demonstration of therapeutic suppression of
apoCIII-induced vascular inﬂammation.
Increasing evidence suggests that apoCIII is a novel and potent
target for the prevention and treatment of CVD. Epidemiological
studies have demonstrated that apoCIII is a strong, independent
predictor of CVD after adjusting for the classical blood lipid risk
factors.
6–8 To elucidate the molecular mechanism behind oversized
atherogenic risk associated with apoCIII, a series of our published
studies documented that apoCIII alone, or as a component of apoB
containing lipoproteins, activated monocytes and EC and enhances
their adhesive interaction in vitro.
15,16 To extend these ﬁndings in
vivo, we administered apoCIII to hypercholesterolaemic mice and
observedthatapoCIIIinducedtheexpressionandaccumulationofad-
hesion molecule VCAM-1 at the aortic endothelium. Together with
ourearlierﬁndings,thislineofevidencesuggeststhatapoCIII-induced
ECactivationandmonocyteadhesionisoneofthemajormechanisms
through which apoCIII induces atherosclerosis.
EC dysfunction is a hallmark of atherosclerotic lesion initiation
and progression. As cells lining the entire inner surface of blood
vessels, vascular EC are perpetually exposed to a wide variety of
blood borne plasma stimulants. Recruitment of monocytes by ad-
hesion to the vascular wall, the ensuing transendothelial migration
and their retention in a complex milieu of pro-atherosclerotic
stimuli drive monocyte transformation into macrophages and
macrophage-derived foam cells.
4,5 In this study, physiological
levels of apoCIII induced the expression of VCAM-1 in vitro and
in vivo and enhanced monocyte adhesion under ﬂow conditions.
Given the importance of EC dysfunction in atherogenesis and its
clinical manifestation (i.e. acute myocardial infarction), one could
theorize that patients with elevated plasma apoCIII are at higher
risk for CVD because of the constant exposure of the vascular
wall to circulating apoCIII-containing lipoproteins. To counter
apoCIII’s direct atherogenic effects, we investigated statin treat-
ment on apoCIII-induced EC dysfunction. In addition to lipid low-
ering, statins may exert anti-inﬂammatory effects in vascular cells.
However, the effects of statins on adhesion molecule expression
in ECs remain controversial. Whereas some studies demonstrated
that statins reduced the VCAM-1 induction in ECs after exposure
to TNF-a,
19,20 others reported that statins enhanced expression of
these adhesion molecules
21,22 or had no effect.
23 From the wide
range of reported effects, it appears that adhesion molecule ex-
pression by statins is greatly inﬂuenced by the experimental
system, including leucocytes and EC types examined, type of
statin experimented, conditions of shear stress, and other
factors. In the present study, by using cultured human primary
C. Zheng et al. 620Figure 5 Pitavastatin administration signiﬁcantly attenuates apoCIII-induced VCAM-1 activation and monocyte inﬁltration in vivo.( A–C) Pita-
vastatin was administered by gavage for 5 days to Ldlr
2/2 mice on a high-fat diet for 3 months at the dosage of 60 mg/day/kg body weight. At the
end of pitavastatin administration, we injected 200 mg of puriﬁed human apoCIII to these mice through the tail vein. After 16 h, we collected
aorta from these mice and examined VCAM-1 protein accumulation at the aortic arch by immunohistochemistry analysis (A and B) and VCAM-1
mRNA levels in the whole aorta by qPCR (C). ‘L’ indicates lumen. Each group had six mice. (D–F) In some other experiments, pitavastatin was
administered by gavage for 5 days to wild-type C57BL/6 mice at the dosage of 60 mg/day/kg body weight. These mice were about 5 months old
and fed on regular chow diet. Dorsal air pouch was created by injection of 3 mL of sterile air subcutaneously, repeated twice every 3 days.
ApoCIII (200 mg in 200 mL PBS) was injected with 3 mL of air. After 24 h, we collected cells from the air pouch by lavage. Inﬁltrated monocytes
and macrophages were stained with the F4/80 antibody, and F4/80+ cell population was determined by FACS analysis. Total cell populations
were gated by side/forward scatter (D inserts) and the F4/80+ population was determined. Representative images (D) and quantiﬁed results
(E and F) from FACS analysis. Data represent mean+SEM. *P , 0.05 between apoCIII treatment and control;
†P , 0.05 between mice treated
with or without pitavastatin (Mann–Whitney test).
Statins suppress apoCIII-induced vascular EC activation and monocyte adhesion 621ECs from saphenous veins and coronary arteries and applying
physiologically relevant levels of laminar shear stress, we demon-
strated that clinically achievable concentrations of statins sup-
pressed apoCIII-induced VCAM-1 expression and monocyte
adhesion without affecting the viability of these cells. Furthermore,
in vivo administration of pitavastatin at clinically relevant dosages
signiﬁcantly reduced VCAM-1 expression in the aorta of hyper-
cholesterolaemic mice after apoCIII injection and also attenuated
the inﬁltration of monocytes and macrophages in a subcutaneous
air pouch model. Collectively, these results indicate that statins
may suppress direct atherogenic effects on EC activation by
apoCIII in patients.
In addition to inhibiting apoCIII-induced EC activation, statins
modestly lower plasma concentrations
24 and hepatic cellular
mRNA levels
25 of apoCIII, independent of their effects on
LDL-receptor activity. Although the precise mechanism for the
effects of statins on apoCIII lowering is not fully understood, it
may relate to the activation of the hepatic PPARa pathway.
26
PPARa agonists have been shown to consistently reduce apoCIII
expression and plasma levels.
27
We and others established that lipid lowering is an anti-
inﬂammatory therapy.
5,17 Diet-induced lipid lowering in hypercho-
lesterolaemic rabbits reduced oxidative stress and EC expression
of VCAM-1.
3 While evidence clearly suggests that the effects of
statin treatment on prevention of coronary events in patients
closely associate with the magnitude of cholesterol reduction,
28
clinical signiﬁcance of statins’ pleiotropic effects remains obscure.
Our results suggested that lipophilic statins exerted more pro-
nounced effects in inhibiting apoCIII-induced VCAM-1 expression
in vascular EC and monocyte adhesion than a hydrophilic statin,
probably via their permeability to peripheral tissues. These data
agree with our earlier publications that reported strong
lipid-independent effects of lipophilic statins.
29,30
Our results demonstrated that apoCIII induced the expression
of VCAM-1 without affecting ICAM-1. The pathophysiological out-
comes of apoCIII differentially mediating the expression of
VCAM-1 and ICAM-1 by vascular ECs remain to be further
studied. Both VCAM-1 and ICAM-1 are expressed in vascular
ECs and play important but different roles in leucocyte recruit-
ment in that VCAM-1 is more important in leucocyte arrest and
ﬁrm adhesion while ICAM-1 in slow rolling and migration.
31,32
Nonetheless, VCAM-1 is a major adhesion molecule that is
expressed by ECs in atherosclerotic plaques and plays an import-
ant role in the initiation of atherosclerosis in animal models.
33
Our study also showed that NF-kB may be a central regulator of
apoCIII-induced EC activation and NF-kB inhibition could be the
major mechanism by which statins reduce apoCIII-induced EC ac-
tivation. The key step in NF-kB regulation is the translocation of
activated NF-kB from the cytoplasm to the nucleus. Our results
demonstrated that statin pre-treatment abolishes apoCIII-induced
nuclear translocation of the NF-kB p65 subunit. Consistent with
our observation, Størling et al.
34 examined apoCIII-induced pan-
creatic b-cell apoptosis, and reported that apoCIII induced IkBa
degradation and NF-kB reporter activity. Previous reports
Figure 6 Pitavastatin suppresses apoCIII-induced NF-kB activation. (A) Conﬂuent HSVECs were incubated with pitavastatin (50 nM) for 12 h
before treatment with puriﬁed human apoCIII (50 mg/mL) for 4 h. After cells were lysed, nuclear and cytoplasmic fractions were isolated.
Western blotting was performed using a monoclonal antibody against the p65 subunit of NF-kB. The density of the bands was scanned and
quantiﬁed. In some other experiments, conﬂuent HSVECs were incubated with (A) an inhibitor for NF-kB for 30 min or (B) inhibitors for
JNK (SP600125, 50 mM), ERK1/2 (PD98059, 20 mM), and p38 (SB203580, 10 mM) for 2 h before treatment with puriﬁed human apoCIII
(50 mg/mL) for 4 h. VCAM-1 expression was determined by qPCR. Data represent mean+SEM. *P , 0.05 between apoCIII treatment and
control [unpaired t-test for (B), Dunnett’s test for (C)];
†P , 0.05 between statin treatment and apoCIII alone (unpaired t-test).
C. Zheng et al. 622showed that statins inhibited the expression of pro-inﬂammatory
cytokines through NF-kB inhibition.
35 Since the NF-kB pathway
plays an important role in apoCIII-induced pro-inﬂammatory and
pro-atherogenic effects in other vascular cells such as monocytes
15
and macrophages (Zheng et al., unpublished observations), statins
may also help to reduce apoCIII’s adverse effects in these cells.
Interestingly, we did not observe evidence for the involvement
of MAP kinases (JNK, Erk1/2, or p38) in apoCIII-induced EC activa-
tion. MAP kinases were previously implied in apoCIII-induced
apoptosis in a rat insulinaemia cell line,
12 but not in primary rat
pancreatic islets.
34 The role of MAPK in apoCIII-induced EC dys-
function remains to be studied.
In conclusion, this study has extended our previous in vitro
observations to demonstrate that apoCIII, a major surface compo-
nent of circulating blood lipoproteins, induces the expression of
the adhesion molecule VCAM-1 in cultured human arterial and
venous ECs. Furthermore, apoCIII also induces aortic EC activation
and monocyte/macrophage inﬁltration in vivo, both of which were
signiﬁcantly reduced by statin administration. Our observations
provide novel insights into the role for apoCIII as a distinct con-
tributor to atherosclerotic lesion initiation and progression.
Statin treatment, especially with lipophilic statins, effectively
reduces apoCIII-induced EC activation both in vitro and in vivo. Al-
though previous studies have shown that statins only modestly
lower plasma apoCIII, our results demonstrate that statins directly
reduce apoCIII-induced endothelial adhesiveness and suggest a
novel vascular protective effect of statins in patients with elevated
plasma levels of apoCIII.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Corrigendum
.............................................................................................................................................................................
doi:10.1093/eurheartj/eht002
Corrigendum to: ‘QRS duration and QRS fractionation on surface electrocardiogram are markers of right ventricular dysfunction
and atrialization in patients with Ebstein anomaly’ [Eur Heart J 2012;34:191–200, doi:10.1093/eurheartj/ehs362].
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